Hualan Biological Vaccine initiates clinical trials for its novel influenza mRNA vaccine.
China's NMPA approved a clinical trial on September 11. Success requires formal registry and enrollment of the first cohort for the candidate.
Across 6 frontier models answering independently, the panel leans yes: the median is 84%.
They broadly agree, 19 points between DeepSeek at 93% and Qwen at 74%.
Nothing is settled until 14 Sept 2027, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
DeepSeekDeepSeek
NMPA approval already granted; trial initiation within 12 months of approval is near-certain.
deepseek/deepseek-v4.1-flash · asked 14 Sept 202693% -
GrokxAI
NMPA IND just granted; China sites typically register and FPI within months, with a full year left.
x-ai/grok-4.6 · asked 14 Sept 202688% -
GeminiGoogle
Once IND approval is granted, initiation of Phase 1 vaccine trials in China typically takes 4-9 months.
google/gemini-3.8-flash · asked 14 Sept 202684% -
GPTOpenAI
NMPA clearance makes first-patient enrollment within a year highly likely, absent development reprioritization.
openai/gpt-5.6-terra · asked 14 Sept 202684% -
ClaudeAnthropic
NMPA approval already granted; ~1 year window is ample for first-cohort enrollment
anthropic/claude-sonnet-5 · asked 14 Sept 202680% -
QwenAlibaba
NMPA approval is the hard gate; formal registry + first-dose enrollment within 12 months is routine but not guaranteed.
qwen/qwen3.8-max-0902 · asked 14 Sept 202674%
6 of 6 models answered · 19 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 14 Sept 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.